Your browser doesn't support javascript.
loading
Progress of Interference of Traditional Chinese Medicine on Cirrhosis Treated with Bone Marrow Mesenchymal Stem Cells.
Wang, Yaxin; Zhang, Huicun; Wang, Hongbing.
Afiliação
  • Wang Y; Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China.
  • Zhang H; Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China.
  • Wang H; Beijing Institute of Traditional Chinese Medicine, Beijing 100010, China.
Article em En | MEDLINE | ID: mdl-34055009
ABSTRACT
Transplantation of bone marrow mesenchymal stem cells has attracted more and more attention as a regenerative therapy for the treatment of liver diseases. A large number of studies have shown that this kind of cells can inhibit the activation of hepatic stellate cells and regulate tissue homeostasis and immune system via a variety of ways. Meanwhile, bone marrow mesenchymal stem cells can inhibit apoptosis of hepatocyte, improve liver function, and reduce inflammation through multiple pathways. These cells have a broad prospect in the treatment of liver cirrhosis. At present, there are many studies on the specific mechanism of bone marrow mesenchymal stem cells transplantation in the treatment of liver cirrhosis. This paper reviews the pathogenesis of liver cirrhosis and the mechanism of bone marrow mesenchymal stem cells transplantation in the treatment of liver cirrhosis, discusses the effectiveness of traditional Chinese medicine method in enhancing the efficacy of bone marrow mesenchymal stem cells transplantation, and looks forward to its application prospect in the future.

Texto completo: 1 Base de dados: MEDLINE Medicinas Tradicionais: Medicinas_tradicionales_de_asia / Medicina_china Idioma: En Revista: Evid Based Complement Alternat Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Medicinas Tradicionais: Medicinas_tradicionales_de_asia / Medicina_china Idioma: En Revista: Evid Based Complement Alternat Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China